Commercial Activist investor renews its criticism of Novavax PharmaphorumShah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."CommercialRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaphorum Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a “destruction in shareholder value.” CommercialRead full story Post navigation Previous: Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make HeadwayNext: Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026